HRP990054A2 - The use of 3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in treating heart failure - Google Patents

The use of 3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in treating heart failure Download PDF

Info

Publication number
HRP990054A2
HRP990054A2 HR60/074,934A HRP990054A HRP990054A2 HR P990054 A2 HRP990054 A2 HR P990054A2 HR P990054 A HRP990054 A HR P990054A HR P990054 A2 HRP990054 A2 HR P990054A2
Authority
HR
Croatia
Prior art keywords
phenoxy
trimethyl
dimethyl
ethyl
pyridine
Prior art date
Application number
HR60/074,934A
Other languages
English (en)
Croatian (hr)
Inventor
Liang Chen Yuhpyng
Anthony Andrea Fossa
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP990054A2 publication Critical patent/HRP990054A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR60/074,934A 1998-02-17 1999-02-17 The use of 3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in treating heart failure HRP990054A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
HRP990054A2 true HRP990054A2 (en) 2000-02-29

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/074,934A HRP990054A2 (en) 1998-02-17 1999-02-17 The use of 3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in treating heart failure

Country Status (28)

Country Link
US (1) US6043260A (fr)
EP (1) EP0951906A1 (fr)
JP (1) JPH11292766A (fr)
KR (1) KR19990072616A (fr)
CN (1) CN1231176A (fr)
AP (1) AP9901464A0 (fr)
AR (1) AR017723A1 (fr)
AU (1) AU1732999A (fr)
BG (1) BG103180A (fr)
BR (1) BR9900653A (fr)
CA (1) CA2262252C (fr)
EA (1) EA199900124A3 (fr)
GT (1) GT199900015A (fr)
HR (1) HRP990054A2 (fr)
HU (1) HUP9900386A3 (fr)
ID (1) ID23218A (fr)
IL (1) IL128531A0 (fr)
IS (1) IS4975A (fr)
MA (1) MA26608A1 (fr)
NO (1) NO990722L (fr)
OA (1) OA10976A (fr)
PA (1) PA8467401A1 (fr)
PE (1) PE20000266A1 (fr)
PL (1) PL331507A1 (fr)
SG (1) SG81261A1 (fr)
TN (1) TNSN99024A1 (fr)
TR (1) TR199900328A2 (fr)
ZA (1) ZA991220B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
WO2001021259A2 (fr) * 1999-09-21 2001-03-29 Emory University Procedes et compositions de traitement des pathologies apparentees aux plaquettes
PL357589A1 (en) * 2000-01-18 2004-07-26 Pfizer Products Inc. Corticotropin releasing factor antagonists
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04007026A (es) 2002-02-22 2004-10-11 Pharmacia & Up John Company Pirimidinonas y pirimidintionas sustituidas.
BR0308391A (pt) * 2002-03-13 2005-01-11 Pharmacia & Upjohn Co Llc Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores
US6964965B2 (en) * 2002-04-26 2005-11-15 Pharmacia & Upjohn Substituted pyrazine derivatives
MXPA05002418A (es) * 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Derivados de 1,4-pirazina sustituidos.
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
WO2004046136A1 (fr) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Composes de pyrazine en tant que modulateurs de crf
JP2006524223A (ja) * 2003-04-23 2006-10-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Crfアンタゴニストとしての置換されたピリミジノンおよびピリミジンチオン
EP1622911A2 (fr) * 2003-05-07 2006-02-08 Pharmacia & Upjohn Company LLC Composes pyrrolo 1,2-b]pyridaziniques
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
EP1625115A1 (fr) * 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Derives pyrimidiques substitues
JP2006525989A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Cns障害を治療するためのcrf1受容体アンタゴニストとしてのピラジノン
US20050209289A1 (en) * 2004-03-16 2005-09-22 Talarico Matthew T Method for vascular dysregulation
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
SG81261A1 (en) 2001-06-19
ZA991220B (en) 2000-08-16
GT199900015A (es) 2000-07-26
CA2262252C (fr) 2006-01-10
PE20000266A1 (es) 2000-04-07
NO990722L (no) 1999-08-18
TNSN99024A1 (fr) 2005-11-10
CA2262252A1 (fr) 1999-08-17
AR017723A1 (es) 2001-09-12
KR19990072616A (ko) 1999-09-27
HUP9900386A3 (en) 1999-12-28
CN1231176A (zh) 1999-10-13
IL128531A0 (en) 2000-01-31
OA10976A (en) 2001-11-05
ID23218A (id) 2000-03-30
EA199900124A3 (ru) 1999-12-29
BG103180A (bg) 1999-09-30
HUP9900386A2 (hu) 1999-11-29
EP0951906A1 (fr) 1999-10-27
AP9901464A0 (en) 1999-03-31
AU1732999A (en) 1999-09-02
MA26608A1 (fr) 2004-12-20
NO990722D0 (no) 1999-02-16
BR9900653A (pt) 2000-10-17
TR199900328A2 (xx) 1999-10-21
EA199900124A2 (ru) 1999-08-26
US6043260A (en) 2000-03-28
IS4975A (is) 1999-08-18
PA8467401A1 (es) 2000-09-29
HU9900386D0 (en) 1999-04-28
JPH11292766A (ja) 1999-10-26
PL331507A1 (en) 1999-08-30

Similar Documents

Publication Publication Date Title
HRP990054A2 (en) The use of 3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine in treating heart failure
US4666908A (en) 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
KR900004693B1 (ko) 4,5,6-치환-n-(치환페닐)-2-피리미딘아민, 그 제조방법 및 그 화합물이 들어있는 조성물
DE60108633T2 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren
JPS62281858A (ja) ピペリジン誘導体及びその類縁誘導体
WO2011160548A1 (fr) Dérivés du 2-aryl imidazo[1,2-α]pyridine-3-acétamide, leurs méthodes de préparation et utilisation
JP4571863B2 (ja) 抗痛覚過敏剤として有用なキナゾリノン誘導体
US20130040988A1 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
US4769384A (en) Benzimidazole derivatives
JP2002326983A (ja) β3アゴニスト及びその使用
JP2007522095A (ja) ジプラシドンを用いた不安の治療
JPS59216877A (ja) 置換フエニル−2−(1h)−ピリミジノン
JP2726999B2 (ja) イミダゾ[2,1−b]ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
JPH03169862A (ja) 新規ピリジン誘導体、それらを含む製薬組成物、およびその製造方法
JPS61238786A (ja) ピリジン誘導体
JPH0377191B2 (fr)
JP2005526113A (ja) 新規なピペリジニル−アルキルアミノ−ピリダジノン誘導体、その製法及びこの化合物を含有する医薬組成物
CZ51399A3 (cs) Farmaceutická kompozice a kit
JPH05504778A (ja) 新規3(2h)―ピリダジノン、それを含む医薬組成物及びその調製方法
JPH0770083A (ja) イミダゾール誘導体を有効成分とする血圧降下剤
JPH05213885A (ja) デカヒドロキノリンの新規な誘導体、それらの製造法、製造中間体、それらの薬剤としての用途及びそれらを含有する組成物
JPS62240677A (ja) カルボスチリル誘導体

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20000217

Year of fee payment: 2

A1OB Publication of a patent application
OBST Application withdrawn